BRCA1/2 pathogenic variants were more frequently detected in patients diagnosed with high-grade serous carcinoma (54 versus 2 [non-high-grade serous carcinoma]) and those with advanced-stage disease (8 [FIGO stage I/II] versus 48 [FIGO stage III/IV]). Here, BRCA1 is linked to serous adenocarcinoma.